Hyloris Pharmaceuticals SA
ISIN: BE0974363955 | Ticker: HYL | LEI: 875500LZIWS7QEQE0I73
Country: Belgium
We are a specialty biopharma company committed to bringing innovative, value-added medicines that address the needs of underserved patient populations.
We apply our knowhow and technological innovations to existing pharmaceuticals to unlock their hidden potential and address unmet medical needs. We have built a broad proprietary pipeline of complex value-added products with potential to offer significant advantages over currently available alternatives.
Today, we have two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a novel, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain.
Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established.
2012
Served areaWorldwide
HeadquartersBoulevard Patience et Beaujonc 3/1, 4000 Rocourt, Liège – Belgium
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Assets | N/A | 69,182,000.00 | 63,444,000.00 |
| Noncurrent Assets | N/A | 2,569,000.00 | 9,485,000.00 |
| Property Plant And Equipment | N/A | 24,000.00 | 122,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 2,381,000.00 | 2,944,000.00 |
| Investments In Subsidiaries Joint Ventures And Associates | N/A | 0.00 | 4,079,000.00 |
| Other Noncurrent Assets | N/A | 0.00 | 1,714,000.00 |
| Current Assets | N/A | 66,613,000.00 | 53,959,000.00 |
| Trade And Other Current Receivables | N/A | 253,000.00 | 2,321,000.00 |
| Other Current Financial Assets | N/A | 7,000.00 | 528,000.00 |
| Cash and cash equivalents | 205,000.00 | 64,399,000.00 | 50,012,000.00 |
| Other Current Assets | N/A | 1,954,000.00 | 1,098,000.00 |
| Equity And Liabilities | N/A | 69,182,000.00 | 63,444,000.00 |
| Equity | -10,188,000.00 | 59,059,000.00 | 48,056,000.00 |
| Issued Capital | N/A | 129,000.00 | 129,000.00 |
| Retained Earnings | N/A | -43,226,000.00 | -54,805,000.00 |
| Share Premium | N/A | 103,693,000.00 | 103,693,000.00 |
| Other Reserves | N/A | -1,537,000.00 | -960,000.00 |
| Liabilities | N/A | 10,123,000.00 | 15,388,000.00 |
| Noncurrent Liabilities | N/A | 7,991,000.00 | 409,000.00 |
| Other Noncurrent Financial Liabilities | N/A | 7,885,000.00 | 300,000.00 |
| Longterm Borrowings | N/A | 106,000.00 | 109,000.00 |
| Current Liabilities | N/A | 2,132,000.00 | 14,978,000.00 |
| Trade And Other Current Payables | N/A | 1,629,000.00 | 2,749,000.00 |
| Current Tax Liabilities Current | N/A | 47,000.00 | 349,000.00 |
| Other Current Financial Liabilities | N/A | 409,000.00 | 11,815,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
|---|---|---|
| Revenue | 175,000.00 | 3,096,000.00 |
| Profit Loss From Operating Activities | -7,025,000.00 | -10,541,000.00 |
| Finance Income | 901,000.00 | 32,000.00 |
| Finance Costs | 1,021,000.00 | 773,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | N/A | -191,000.00 |
| Profit Loss Before Tax | -7,145,000.00 | -11,282,000.00 |
| Income Tax Expense Continuing Operations | 1,000.00 | 297,000.00 |
| Profit (loss) | -7,145,000.00 | -11,579,000.00 |
| Profit Loss Attributable To Owners Of Parent | -7,145,000.00 | -11,579,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | N/A |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Profit (loss) | N/A | -7,145,000.00 | -11,579,000.00 |
| Adjustments For Sharebased Payments | N/A | 485,000.00 | 576,000.00 |
| Other Adjustments For Noncash Items | N/A | -17,000.00 | -1,000.00 |
| Cash Flows From Used In Operations | N/A | -4,571,000.00 | -11,253,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | -1,000.00 | -3,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -4,570,000.00 | -11,250,000.00 |
| Other Cash Payments To Acquire Interests In Joint Ventures Classified As Investing Activities | N/A | 0.00 | 1,270,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | 107,000.00 |
| Proceeds From Sales Of Intangible Assets Classified As Investing Activities | N/A | N/A | 219,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 623,000.00 | 954,000.00 |
| Purchase Of Other Longterm Assets Classified As Investing Activities | N/A | 10,000.00 | 21,000.00 |
| Cash Advances And Loans Made To Other Parties Classified As Investing Activities | N/A | N/A | 1,157,000.00 |
| Cash Receipts From Repayment Of Advances And Loans Made To Other Parties Classified As Investing Activities | N/A | N/A | 216,000.00 |
| Other Inflows Outflows Of Cash Classified As Investing Activities | N/A | 0.00 | N/A |
| Cash Flows From Used In Investing Activities | N/A | -633,000.00 | -3,075,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 51,000.00 | 62,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 69,397,000.00 | -62,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 64,194,000.00 | -14,387,000.00 |
| Cash and cash equivalents | 205,000.00 | 64,399,000.00 | 50,012,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 13.06.23 | Aichhorn Dietmar | Executive member | Buy | EUR 144,375.00 |
| 13.06.23 | Vandebroek Jean-Luc | Executive member | Buy | EUR 69,300.00 |
| 14.04.22 | Van der Elst Koenraad | Executive member | Sell | EUR 56,466.40 |
| 22.03.22 | Aichhorn Dietmar | Executive member | Buy | EUR 347,000.00 |
| 22.03.22 | Vandebroek Jean-Luc | Board | Buy | EUR 52,050.00 |
BE0974363955
LEI875500LZIWS7QEQE0I73
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.